Cargando…

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration

BACKGROUND: Faropenem (F), an orally bioavailable β-lactam, kills Mycobacterium tuberculosis (Mtb) without the help of a β-lactamase inhibitor. This study explored the sterilizing effect of adding F once or twice daily to a linezolid (L) plus pyrazinamide (Z) backbone regimen. METHODS: In vitro stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gumbo, Tawanda, Sherman, Carleton M., Deshpande, Devyani, Alffenaar, Jan-Willem, Srivastava, Shashikant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168785/ https://www.ncbi.nlm.nih.gov/pubmed/33556616 http://dx.doi.org/10.1016/j.ijid.2021.01.062

Ejemplares similares

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way
por: Deshpande, Devyani, et al.
Publicado: (2016)

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2017)

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps
por: Deshpande, Devyani, et al.
Publicado: (2016)

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo
por: Deshpande, Devyani, et al.
Publicado: (2016)

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases
por: Deshpande, Devyani, et al.
Publicado: (2016)

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis
por: Deshpande, Devyani, et al.
Publicado: (2018)

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy
por: Deshpande, Devyani, et al.
Publicado: (2022)

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis
por: Deshpande, Devyani, et al.
Publicado: (2017)

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence
por: Pasipanodya, Jotam G., et al.
Publicado: (2017)

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Comment on “Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections”
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
por: Vinnard, Christopher, et al.
Publicado: (2017)

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2016)

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution
por: Gonzalo, Ximena, et al.
Publicado: (2020)

Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
por: Gumbo, Tawanda, et al.
Publicado: (2023)

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
por: Swaminathan, Soumya, et al.
Publicado: (2016)

2447. Ertapenem and Faropenem for the Treatment of Drug-Resistant Tuberculosis
por: Satta, Giovanni, et al.
Publicado: (2018)

Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis
por: Werngren, Jim, et al.
Publicado: (2021)

The pyrazinamide susceptibility breakpoint above which combination therapy fails
por: Gumbo, Tawanda, et al.
Publicado: (2014)

1659. Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease
por: Deshpande, Devyani, et al.
Publicado: (2020)

Generalized Bullous Drug Eruption to Faropenem - Hitherto Unreported
por: Gangopadhyay, Anusree, et al.
Publicado: (2017)

Host Targeted Activity of Pyrazinamide in Mycobacterium tuberculosis Infection
por: Manca, Claudia, et al.
Publicado: (2013)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis
por: Ahmad, Zahoor, et al.
Publicado: (2012)

Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System
por: Boorgula, Gunavanthi D., et al.
Publicado: (2021)

Role of Faropenem in Treatment of Pediatric Infections: The Current State of Knowledge
por: Nayak, Sumitha, et al.
Publicado: (2022)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study
por: Miotto, Paolo, et al.
Publicado: (2014)

The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
por: Sun, Qingan, et al.
Publicado: (2020)

Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide
por: Santucci, Pierre, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_icrp84fmnqevbv0t3oc0q2dpt4